Solasia Pharma K.K. revised consolidated financial guidance for the fiscal year ending December 31, 2022. For the year, the company expects revenue of ¥1,150 million, operating loss of ¥2,350 million, loss attributable to owners of parent of ¥2,450 and basic loss per share of ¥14.60 compared to previous guidance of revenue of ¥1,150 million, operating loss of ¥2,150 million, loss attributable to owners of parent of ¥2,250 and basic loss per share of ¥13.41.
Market Closed -
Other stock markets
|
5-day change | 1st Jan Change | ||
26 JPY | 0.00% | 0.00% | -42.22% |
EPS Revisions
1st Jan change | Capi. | |
---|---|---|
-42.22% | 30.21M | |
-3.45% | 87.17B | |
+2.76% | 40.1B | |
-16.98% | 31.38B | |
+57.86% | 25.12B | |
-16.24% | 15.59B | |
-9.12% | 12B | |
-42.56% | 11.8B | |
-17.10% | 11.8B | |
+6.89% | 8.81B |
- Stock Market
- Equities
- 4597 Stock
- News Solasia Pharma K.K.
- Solasia Pharma K.K. Revises Consolidated Financial Guidance for the Fiscal Year Ending December 31, 2022